Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125176012 | 12517601 | 2 | F | 20160426 | 20160628 | 20160630 | 20160705 | EXP | PHHY2016IT087414 | NOVARTIS | 44.99 | YR | M | Y | 0.00000 | 20160705 | OT | IT | IT |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125176012 | 12517601 | 1 | PS | TASIGNA | NILOTINIB | 1 | Oral | 600 MG, QD | 1247400 | MG | 22068 | 600 | MG | CAPSULE | QD |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125176012 | 12517601 | 1 | Chronic myeloid leukaemia |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
125176012 | 12517601 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125176012 | 12517601 | Aortic occlusion | |
125176012 | 12517601 | Intermittent claudication | |
125176012 | 12517601 | Pain | |
125176012 | 12517601 | Peripheral artery occlusion |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
125176012 | 12517601 | 1 | 20100827 | 20160505 | 0 |